What exactly is the Technosphere® Platform?

NTM Lung Disease on the Rise

Share & Print option

Release Details

MannKind to Present at Upcoming Conferences

04/27/10
MannKind to Present at Upcoming Conferences

VALENCIA, Calif., Apr 27, 2010 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

  • Deutsche Bank 35th Annual Health Care Conferenceon Tuesday, May 4, 2010 at 4:50 PM (EDT) at the InterContinental in Boston, MA
  • Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 12, 2010 at 3:00 PM (EDT) at the Grand Hyatt in New York, NY
  • Rodman & Renshaw 6th Annual Global Healthcare Conference on Monday, May 17, 2010 at 10:40 AM (London Time) at the Grosvenor House Hotel in London, UK

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA™ and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response from the FDA regarding this NDA seeking additional information about AFREZZA. Currently, AFREZZA remains under regulatory review. Other products in its pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com